Washington: A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine, an antimalarial drug, for the treatment of adults hospitalized with COVID-19 has begun in the United States.
This was informed through a release of the National Institutes of Health (NIH) on Thursday.
The NIH’s National Heart, Lung, and Blood Institute (NHLBI) announced Thursday that the first patients had been enrolled at Vanderbilt University Medical Center in Nashville in the trial of hydroxychloroquine to assess its safety and efficacy in treating COVID-19 patients.
The blinded, placebo-controlled randomized clinical trial aims to enroll more than 500 adults who are currently hospitalized with COVID-19 or in an emergency department with anticipated hospitalization.
All participants in the study will continue to receive clinical care as indicated for their condition. Those randomized to the experimental intervention will also receive hydroxychloroquine, according to the NIH.
President Trump’s assertive backing of the drug as a COVD-19 treatment before any clinical evidence was available to prove it safe and effective for that use put him at odds with his own senior medical experts.